A panel of key stakeholders in the pharmacy field discuss the nature of environmental conditions as a social determinant of health and the potential impact on patient health outcomes, as well as how to best educate patients and colleagues when approaching the subject in the pharmacy.
Octagam 10% is indicated for the treatment of chronic immune thrombocytopenic purpura in adults and dermatomyositis (DM) in adults
The panel discusses the possible prescription treatments for dry eye disease.
With consideration of recent COVID-19 vaccine approval in adolescents, Jennifer Adams, PharmD, EdD, discusses pharmacy’s role in immunizing children of all ages.
The new format being rolled out at Rite Aid stores is designed to center pharmacists and make them easily accessible to patients.
Emerging combination therapies and novel agents being studied as initial therapy for CLL are discussed.
In the latest Student Cafe interview series, students from the University of Texas at Austin College of Pharmacy discussed the future of pharmacy after the COVID-19 pandemic.
In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.
A panel of pharmacists and doctors explain when a patient should seek professional help for dry eye disease.
Study examines whether dapagliflozin is cost-effective when added to standard of care for patients who have heart failure with reduced ejection fraction.
In the latest Student Cafe interview series, students from the University of Texas at Austin College of Pharmacy discussed the future of pharmacy after the COVID-19 pandemic.
Suzanne Soliman, PharmD, BCMAS, discusses how pharmacy can help communities catch up on missed and overdue immunizations resulting from the COVID-19 pandemic.
Monazzah Akbar Sarwar, PharmD, continues the conversation for over-the-counter treatment options for patients with dry eye disease.
In this third video in a series collaboration between Pharmacy Times and USP, Jeanne Sun, PharmD, JD, counsel, legal at USP, discusses information to help pharmacists counsel patients on quality expectations in the pharmacy.
John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, shares his view of what pharmacists contribute to health care.
In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.
Experts provide advice for community pharmacists wanting to explore options, such as Prescription Discount Programs, to help improve their patients’ outcomes.
Experts discuss factors and approaches to consider if choosing between a BTKi-based and BCL2i-based regimen for frontline therapy in CLL.
Thomas Maggio, MBA, public affairs and engagement manager at AACP, discussed his presentation assessing the Opioid-Related Activity Database and its impact in showing the efforts of pharmacists and student pharmacists to fight the opioid epidemic.
John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discusses the 3 main insights that have guided him throughout his career.
Clive Ward Able, MD, BPharm, discusses research results suggesting the promise of psilocybin as a potential treatment for obesity.
Anna Legreid Dopp, PharmD, CPHQ, senior director of clinical guidelines and quality improvement at ASHP, said their organization was proud to sign onto a recent statement urging health care organizations to mandate COVID-19 vaccines for their employees.
Jennifer Adams, PharmD, EdD, share thoughts on why right now is the perfect opportunity to advocate for expansion of privileges to advance pharmacy practice.
Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss how to manage the logistical challenges that arise during the administration of CAR T therapy in inpatient and outpatient settings for patients with multiple myeloma.
John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discusses his plans for the future of the organization.
In addition to getting outside and taking time to enjoy hobbies outside of work, Carroll urged pharmacists to enjoy time with family and friends whenever possible.
A discussion on some additional services available that could be beneficial for patients, including telemedicine, lab work, and monthly membership programs.
Kirollos S. Hanna, PharmD, BCPS, BCOP, discusses data on a BCL2 inhibitor in combination with anti-CD20 monoclonal antibodies in the treatment of CLL.
Vviloxazine (Qelbree) is a norepinephrine reuptake inhibitor that provides a new treatment option for patients aged 6 to 17 years with ADHD.
John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discusses what led to his interest in the position.
